July 23, 2021 9:50 AM 28 seconds read

Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate

by Vandana Singh Benzinga Editor
Follow
Comments
  • Cortexyme Inc CRTX has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease.
  • COR803 is a novel patent-pending small molecule 3CLpro inhibitor, and 3CLpro (Mpro) is a validated antiviral drug target shown to be essential in viral replication of SARS-CoV-2. 
  • The company is advancing its disease-modifying GAIN Trial in mild to moderate Alzheimer's disease, with top-line data expected in Q4 of 2021.
  • Price Action: CRTX shares are up 1.02% at $65.15 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted In:
BiotechNewsHealth CareSmall CapGeneralBriefs

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved